Open an account

Cingulate

CING · NASDAQ

$4.53+$0.17 (+3.90%)TodayMarket closed ·
Prev close $4.36

About CING

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 14 full-time employees. The company went IPO on 2021-10-07. The firm offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. The company develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). The company also develops CTx-2103 (buspirone), for the treatment of anxiety.

Employees
14
Headquarters
Kansas City, Kansas
Listed
Oct 7, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
cingulate.com

CING key statistics

Market cap
65.87M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
93.59K
Volume
108.42K
Open price
$4.37
High today
$4.64
Low today
$4.24
52 Week high
$11.89
52 Week low
$3.16

Cingulate (CING) at a glance

Cingulate (CING) last traded at $4.53, with a market cap of 65.87M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.24 and $4.64. The current price is 6.8% above the day's low and 2.3% below its high.

Volume so far is 108.42K shares, in line with the average of 93.59K shares a day.

Over the past year Cingulate has ranged from $3.16 to $11.89, and now sits 16% of the way up that range.

Cingulate met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.45 per share against an estimate of -$0.6375.

The average analyst price target is $21.62, 377.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $21.62
Low
$8.08
Now
$4.53
High
$46.20

CING earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 26.7% on average.

  1. Q3 FY24: reported -$1.83 per share against an estimate of -$2.41
  2. Q4 FY24: reported -$4.02 per share against an estimate of -$1.48
  3. Q1 FY25: reported -$1.04 per share against an estimate of -$1.03
  4. Q2 FY25: reported -$1.09 per share against an estimate of -$0.8942
  5. Q3 FY25: reported -$1.35 per share against an estimate of -$0.8262
  6. Q4 FY25: reported -$0.932 per share against an estimate of -$0.6446
  7. Q1 FY26: reported -$0.95 per share against an estimate of -$0.4556
  8. Q2 FY26: reported -$0.45 per share against an estimate of -$0.6375

CING news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

  • Chris Katje

    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?

  • Vaishali Prayag

    What's Going On With Cingulate Shares Recently?

  • Watching Cingulate; Zacks Small-Cap Research Gives stock $70 Price Valuation

  • Avi Kapoor

    Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

  • Avi Kapoor

    Nasdaq Surges 150 Points; Sonder Holdings Shares Surge

  • Avi Kapoor

    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Similar companies

Companies in the same industry as Cingulate

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.